New Diabetes Study Reveals Hidden Hormonal Culprit in 24% of Patients

New Diabetes Study Reveals Hidden Hormonal Culprit in 24% of Patients

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

New Diabetes Study Reveals Hidden Hormonal Culprit in 24% of Patients

A recent trial has revealed that nearly a quarter of patients with hard-to-manage type 2 diabetes also suffer from hypercortisolism, a condition linked to excess cortisol. The findings come from Corcept Therapeutics’ CATALYST study, which tested the effects of Korlym, a cortisol-modulating drug, alongside standard diabetes treatments. Researchers now suggest that screening for this hormonal imbalance could improve care for those struggling with the disease. The CATALYST trial focused on patients whose type 2 diabetes remained poorly controlled despite treatment. Results showed that 24% of these individuals had hypercortisolism, a figure that climbed to 36.6% among those with both resistant hypertension and diabetes. A separate study, MOMENTUM, similarly found that 27.3% of patients with resistant hypertension alone exhibited the condition.

Patients in CATALYST who received Korlym saw significant improvements. Their HbA1c levels dropped by 1.3% on average, a change deemed both clinically meaningful and statistically significant. They also lost 5.1 kg in body weight, reduced their BMI by 1.7 kg/m², and trimmed 5.1 cm from their waistlines compared to the placebo group.

The benefits were even more pronounced when Korlym was combined with GLP-1 receptor agonists or tirzepatide. These patients experienced greater reductions in HbA1c, weight, BMI, and waist size than those on placebo. According to the data, cortisol modulation may enhance the effectiveness of existing diabetes medications.

Lance Sloan, President of the Texas Institute for Kidney and Endocrine Disorders, emphasised the importance of these findings. He noted that identifying hypercortisolism and targeting cortisol could become a crucial step for patients who don’t respond well to standard treatments. The results highlight a potential shift in diabetes management, particularly for those with resistant cases. Korlym’s ability to lower HbA1c, weight, and other metabolic markers—especially when paired with GLP-1 drugs—suggests a new avenue for treatment. Corcept’s Chief Development Officer, Bill Guyer, hopes the research will encourage wider screening for hypercortisolism and lead to better outcomes for patients.

Neueste Nachrichten